China’s latest NRDL update continues to exclude foreign PD-1 inhibitors, favours rare disease drugs
China’s much-anticipated update of its National Reimbursement Drug List (NRDL) presents a mixed bag for overseas pharma. Overall, there were…
All articles by Sophie Cairns
Sophie Cairns
-
-
Delytact: The world’s first oncolytic virotherapy for brain cancer
The world's first oncolytic virus therapy for brain cancer was approved earlier this month - but it was not, as…
-
Japan’s new CEA-based price adjustments set to maintain pricing pressure on innovative drugs
Over the past several years, Japan - which reimburses 99% of all medicines approved in the country - has introduced…
-
China’s young biosimilars sector
China's young biosimilars sector saw a major milestone in December which underlines the sector's rapid growth and significant promise: the…
-
South Korean pharma dreams struggle
In September, South Korean drugmaker Hanmi Pharmaceutical signed a collaboration agreement with US biotech Phanes Therapeutics focusing on dual- and…
-
Inconsistent application of pricing policies in China contributes to pockets of high prices
China's efforts to rein in high medicine prices seem to have hit warp speed. In the last two years alone,…
-
HTA adoption in Asian emerging pharma markets
Asia's emerging markets - such as Indonesia, Vietnam, and the Philippines - may provide a significant growth opportunity of pharmaceutical…
-
Regulatory convergence or divergence for Asian pharma
Asia is seeing increasing convergence between some of its major markets and the United States and Europe, according to the…
-
Culture shift at Takeda a sign of things to come
Takeda's pursuit of UK pharma major Shire has not only made headlines over the last few months, it also heralds…
-
US tariffs likely to mostly affect US generics makers
On 3 April, the Trump administration threatened to place tariffs of 25% on more than 1,300 Chinese goods worth approximately…